News & Events
Spotlight on Innate Immune Science, September 2020: BAF's Role in Innate Immunity; STING Activation in Antitumor Activity
In this monthly series, our scientific advisors break down the latest research and trends in innate immune system science from leading publications and institutions.
Featured Study: IFM Due Co-founder Andrea Ablasser Leads Research on BAF’s Role in Activating Innate Immune System
Summary:herefore, we can conclude that BAF plays a crucial role in preventing the cell from mounting an immune response to its own DNA.
So What:These studies revealed a safeguard mechanism by which cells protect themselves against aberrant immune responses toward genomic DNA. Understanding the interaction between BAF and cGAS adds a new layer of control to prevent aberrant innate immune system activation, and therefore, may enable the development of more precise treatment options for autoimmune or autoinflammatory diseases.
Recent Study Gives Insight Into STING Relationship to Antitumor Immunity
Summary: In a study published in Science, scientists at the Scripps Research Institute in La Jolla, California identified new Stimulator of Interferon Genes (STING) agonists and studied their roles in antitumor immunity. STING is a natural immune-boosting protein that is known for its strong antitumor properties because it marshals the immune system against viral invaders and cancers. STING links innate immunity to biological processes ranging from antitumor immunity to microbiome homeostasis. The Scripps team screened a set of small molecules with diverse structures and identified several that activate STING. Studies found the small molecule, SR-717, functions as a direct cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) mimic that induces the same “closed” conformation of STING. SR-717 displayed antitumor activity, promoted the activation of CD8+ T cells and facilitated antigen cross-priming.
So What: The study results represent progress toward harnessing STING agonists for cancer immunotherapy. STING is a hot yet challenging target in immuno-oncology but is a familiar area of expertise for IFM. In 2017, IFM’s STING agonist program was acquired by Bristol-Myers Squibb and is now being tested clinically. IFM’s STING antagonist program for inflammation and autoimmunity is the subject of a collaboration and option agreement with Novartis. Additional research into STING and the role it plays in disease can lead to new and innovative therapeutic options.
New Study Reveals Sex Can Determine Immune Response for Disease Outcomes
Summary: Researchers at the Yale University School of Medicine in New Haven, Connecticut examined COVID-19 patients who had not received immuno-modulatory medications to determine any sex differences in viral loads, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody titers, plasma cytokines and blood cell phenotyping. Their observations, published in Nature, revealed that male patients showed higher plasma levels of innate immune cytokines such as IL-8 and IL-18, while female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection. Importantly, a poor T cell response negatively correlated with patients’ age and was associated with worse disease outcome in male patients, but not in female patients. The team also found higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.
So What: These conclusions suggest a possible explanation for the observed sex biases in outcomes for COVID-19 patients. Results from this research might inform new and better treatment options for patients fighting coronavirus.
Stay tuned next month for additional studies and perspectives shared by the IFM R&D Team!